Pharmacology
The cannabinoid receptor type 2 (CB2 receptor), encoded by the CNR2 gene, is a G protein-coupled receptor that is part of the endocannabinoid system. Unlike the predominantly central CB1 receptor, CB2 is primarily expressed on immune cells and in peripheral tissues, where it modulates inflammation, pain, and immune responses. Its discovery in the 1990s opened new avenues for therapeutic targeting without the psychoactive effects associated with CB1 activation.
The CB2 receptor was first cloned in 1993 by Sean Munro and colleagues from the MRC Laboratory of Molecular Biology in Cambridge, UK, using degenerate PCR based on the CB1 sequence1. The human CNR2 gene maps to chromosome 1p36.11 and encodes a 360-amino-acid protein with seven transmembrane domains, typical of G protein-coupled receptors2. CB2 shares about 44% amino acid identity with CB1, with the highest conservation in the transmembrane regions. Unlike CB1, which is highly expressed in the central nervous system, CB2 is predominantly found on cells of the immune system, including B lymphocytes, natural killer cells, and macrophages3. The receptor couples to Gi/o proteins, inhibiting adenylyl cyclase and modulating mitogen-activated protein kinase pathways4.
CB2 activation modulates immune cell migration, cytokine release, and apoptosis, playing a key role in resolving inflammation3. In the central nervous system, CB2 is expressed at low levels in microglia and is upregulated during neuroinflammation, as seen in Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis5. CB2 agonists have shown analgesic effects in preclinical models of neuropathic and inflammatory pain, without the psychotropic side effects of CB1 activation6. In bone, CB2 regulates osteoclast and osteoblast activity, influencing bone mass and osteoporosis progression7. The receptor also plays a role in liver fibrosis, atherosclerosis, and cancer cell proliferation, making it a promising therapeutic target for multiple conditions8.
Selective CB2 agonists, such as JWH-133 and HU-308, have been developed to harness anti-inflammatory and analgesic effects while avoiding central side effects6. Inverse agonists like SR144528 have been used to study receptor function and have shown potential in modulating immune responses1. Clinical trials have investigated CB2 agonists for pain management, though none have yet received regulatory approval8. The receptor's role in modulating the tumor microenvironment has sparked interest in CB2-based cancer immunotherapy5. Additionally, CB2 polymorphisms have been linked to susceptibility to autoimmune diseases and osteoporosis, suggesting a genetic component in its pathophysiological roles7.
Beyond immune cells, CB2 is expressed in keratinocytes, where it influences skin barrier function and wound healing3. It also appears in the gastrointestinal tract, modulating gut motility and secretion, and in the reproductive system, affecting sperm function4. CB2 has been detected in the brain's reward circuitry under certain conditions, challenging the notion of it being exclusively peripheral5. The receptor's splice variant, CB2B, has been identified in human testis and may have distinct signaling properties2. In veterinary medicine, CB2-targeting drugs are being explored for treating inflammatory diseases in dogs and horses8. Additionally, certain plant cannabinoids like beta-caryophyllene, a common dietary compound, act as selective CB2 agonists, suggesting a nutritional influence on immune function6.
This article is for informational purposes and does not constitute medical advice.
Help improve the encyclopedia. Reports go straight to the site manager.